welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy
study id #: NCT03532542
condition: Duchenne Muscular Dystrophy
status: enrolling by invitationpurpose:
The main objective of this study is to evaluate the safety and tolerability of long-term treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).
intervention: Casimersen, Golodirsen
mechanism of action: Exon-skipping to promote dystrophin production
last updated: July 19, 2019
start date: August 2, 2018
estimated completion: June 30, 2026
phase of development: Phase 3
size / enrollment: 260
- Number of patients with serious adverse events (SAEs) [Time Frame: Up to 30 days after the last infusion of study drug (assessed up to 148 weeks)]]
• Completed a clinical trial evaluating casimersen or golodirsen, per protocol.
• Is between 7 and 23 years of age, inclusive, at enrollment.
Wave Life Sciences Duchenne Muscular Dystrophy Clinical Trial Selected for FDA Complex Innovative Trial Designs Pilo...Wave Life Sciences Ltd., a biotechnology...
A Randomized, Double-blind, Placebo-controlled Study of SRP-9001 for Duchenne Muscular Dystrophy (DMD)The purpose of this study is to evaluate...
Sunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular DystrophyThe aim of this multicentre, prospective...
Study of ataluren in previously treated participants with nonsense mutation dystrophinopathy (nmDBMD)The objective of this study is to assess...
An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation DystrophinopathyThe primary objective of this study is t...
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular DystrophyDystrophinopathy is a disease continuum ...
Sarepta Therapeutics Statement on ICER Draft Evidence Report for Treatments for Duchenne Muscular DystrophySarepta Therapeutics, Inc., the leader...
Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double...Background: Duchenne muscular dystrophy...
Roche Letter to the Duchenne CommunityBy now, many have heard about Pfizer's d...
ICER Releases Draft Evidence Report on Treatments for Duchenne Muscular DystrophyThe Institute for Clinical and Economic ...